Cargando…

PD-1/CTLA-4 Blockade Leads to Expansion of CD8(+)PD-1(int) TILs and Results in Tumor Remission in Experimental Liver Cancer

BACKGROUND: Checkpoint inhibitors act on exhausted CD8<sup>+</sup> T cells and restore their effector function in chronic infections and cancer. The underlying mechanisms of action appear to differ between different types of cancer and are not yet fully understood. METHODS: Here, we esta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bufe, Sandra, Zimmermann, Artur, Ravens, Sarina, Prinz, Immo, Buitrago-Molina, Laura Elisa, Geffers, Robert, Woller, Norman, Kühnel, Florian, Talbot, Steven R., Noyan, Fatih, Manns, Michael Peter, Wedemeyer, Heiner, Hardtke-Wolenski, Matthias, Jaeckel, Elmar, Davalos-Misslitz, Ana C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267567/ https://www.ncbi.nlm.nih.gov/pubmed/37325488 http://dx.doi.org/10.1159/000526899

Ejemplares similares

The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis
por: Dywicki, Janine, et al.
Publicado: (2021)

Splenectomy induces biochemical remission and regeneration in experimental murine autoimmune hepatitis
por: Dywicki, Janine, et al.
Publicado: (2022)

Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis
por: Buitrago-Molina, Laura Elisa, et al.
Publicado: (2021)

Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration
por: Buitrago-Molina, Laura Elisa, et al.
Publicado: (2021)

Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors
por: Kremer, Jakob, et al.
Publicado: (2022)

Increased apoptosis of regulatory T cells in patients with active autoimmune hepatitis
por: John, Katharina, et al.
Publicado: (2017)

Human γδ TCR Repertoires in Health and Disease
por: Fichtner, Alina Suzann, et al.
Publicado: (2020)

Alloantigen-Induced Regulatory T Cells Generated in Presence of Vitamin C Display Enhanced Stability of Foxp3 Expression and Promote Skin Allograft Acceptance
por: Nikolouli, Eirini, et al.
Publicado: (2017)

Development of Beta-Amyloid-Specific CAR-Tregs for the Treatment of Alzheimer’s Disease
por: Saetzler, Valerie, et al.
Publicado: (2023)

TIL therapy and anti-CTLA4: can they co-exist?
por: Forget, Marie-Andrée, et al.
Publicado: (2019)

Generation of Chimeric Antigen Receptors against Tetraspanin 7
por: Pieper, Tom, et al.
Publicado: (2023)

Deciphering Microenvironment of NSCLC based on CD8+ TIL Density and PD-1/PD-L1 Expression
por: Lin, Ziying, et al.
Publicado: (2019)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Hyperferritinemia and hypergammaglobulinemia predict the treatment response to standard therapy in autoimmune hepatitis
por: Taubert, Richard, et al.
Publicado: (2017)

Corrigendum: Systematic pattern analyses of Vδ2(+) TCRs reveal that shared “public” Vδ2(+) γδ T cell clones are a consequence of rearrangement bias and a higher expansion status
por: Deng, Lihua, et al.
Publicado: (2022)

Systematic pattern analyses of Vδ2(+) TCRs reveal that shared “public” Vδ2(+) γδ T cell clones are a consequence of rearrangement bias and a higher expansion status
por: Deng, Lihua, et al.
Publicado: (2022)

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions
por: Teng, Feifei, et al.
Publicado: (2016)

Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy
por: Ravens, Sarina, et al.
Publicado: (2018)

Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer
por: Ju, Xiaoli, et al.
Publicado: (2017)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Concordance, Correlation, and Clinical Impact of Standardized PD-L1 and TIL Scoring in SCCHN
por: De Keukeleire, Stijn Jeroen, et al.
Publicado: (2022)

Exchange of Cytosolic Content between T Cells and Tumor Cells Activates CD4 T Cells and Impedes Cancer Growth
por: Hardtke-Wolenski, Matthias, et al.
Publicado: (2013)

Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
por: Harter, Patrick N., et al.
Publicado: (2015)

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome
por: Bekos, Christine, et al.
Publicado: (2021)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
por: Porcellato, Ilaria, et al.
Publicado: (2021)

ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
por: Hernandez-Cordero, Nicole, et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic
por: Callahan, Margaret K., et al.
Publicado: (2015)

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
por: Heinzerling, Lucie, et al.
Publicado: (2016)

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
por: Rotte, Anand
Publicado: (2019)

Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1
por: Hao, Yuwei, et al.
Publicado: (2022)

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
por: Yang, Hui, et al.
Publicado: (2013)

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
por: Hupa-Breier, Katharina Luise, et al.
Publicado: (2021)

Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
por: Quezada, S A, et al.
Publicado: (2013)

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
por: Lee, Hyun Tae, et al.
Publicado: (2019)

SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
por: Aghbash, Parisa Shiri, et al.
Publicado: (2021)

Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
por: Xu, Li, et al.
Publicado: (2022)

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cjlrc24c0v3pe8hd7orflhaj74